Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Targovax ASA ( (GB:0RIS) ).
Circio Holding ASA has introduced a broad stock option program for all employees, issuing 5 million options to management and staff as part of its long-term incentive plan following a successful NOK 70 million capital raise. The move is designed to retain key expertise while limiting potential dilution to about 4%, with options priced at NOK 1.18 and subject to a multi-year vesting schedule, underscoring management’s alignment with shareholders and the company’s growth ambitions in advanced RNA-based therapeutics.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing novel circular RNA expression technology for gene and cell therapies. Through its proprietary circVec platform, the company aims to enhance RNA stability and protein expression for use in genetic medicine, cell therapy and chronic disease, while also advancing its TG01 peptide vaccine for RAS-mutated cancers via external collaborations in Norway and the U.S.
Average Trading Volume: 4,050,911
Current Market Cap: NOK202.5M
Learn more about 0RIS stock on TipRanks’ Stock Analysis page.